Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)

Completed · Not applicable

Conditions studied: Hematologic Neoplasms, Graft-Versus-Host Disease

In brief

The purpose of this study is to determine the safety and efficacy of post-transplant cyclophosphamide and a post-transplant infusion of donor cells, that have been specially processed to remove alpha beta t-cells, in patients undergoing a haploidentical allogeneic stem cell transplant to help reduce the risk of relapse without increasing the risk of graft-versus-host disease.

Key facts

Study ID

NCT02193880

Run by

Ayman Saad

People needed

7

Starts

2014-10-09

Expected to finish

2018-03-13

Last updated by the study team

2019-04-25

Who can join

Age: 19 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Neoplastic hematological disorder with indication of allogeneic transplant
• No available suitable HLA-matched donor
• Adequate cardiac, pulmonary, renal, and hepatic function
• Karnofsky performance status score greater than or equal to 70%

You may not qualify if…

• Medication non-compliance
• No appropriate caregiver identified
• Uncontrolled medical or psychiatric disorder
• Active central nervous system (CNS) neoplastic involvement
• Known allergy to Dimethyl Sulfoxide
• HIV1 or HIV2 positive
• Pregnant or breastfeeding

Where it is running

• UAB Medical Center (University of Alabama at Birmingham) — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.